Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Live Ventures held its fiscal Q2 2026 call on May 14, but the transcript provided no financial figures. The stock's next move hinges on the 10-Q filing.
The May 14 earnings call transcript omitted Q3 financial details. The full 10-Q for the March 31 quarter remains pending, creating an information gap for RSSS stock.
The May 14 call transcript lists CEO Gregory Haskell and Chief Growth Officer Roland Austrup but no revenue or guidance. The 10-Q filing is the next data point.
Legacy Education ($LGCY) posted 15% revenue growth and margin gains in Q3, outlining campus expansions to add 1,200-1,500 students. Cash-rich balance sheet.
The May 14 call transcript provided no revenue, margin, or enrollment figures. Investors now await the 10-Q filing for the quarter's actual performance.
Avita Medical posted $19.3M in Q1 revenue and reaffirmed its $80M-$85M full-year view. Medicare rate normalization removes the key adoption headwind; the 2H revenue ramp is the next catalyst.
Professional services revenue fell 14.3% to $1.9M, extending a post-renewal slump. SaaS held flat. Cash of $2.1M and no debt provide runway; the double-digit SaaS growth target now requires a sharp acceleration.
The natural-gas utility published its fiscal Q2 2026 presentation. Investors must wait for the 10-Q and call transcript to see any actual results.
Octave Specialty Group published its Q1 2026 earnings slide deck without financial statements, leaving the stock in a holding pattern until the 10-Q filing provides the numbers needed to reprice shares.
Barfresh Food Group's Q1 2026 call transcript omitted all financials. The 10-Q filing will reveal revenue, margin, and cash burn that could confirm or disrupt the growth narrative.
The fiscal Q3 2026 earnings call transcript for ReposiTrak contains no financial figures. Investors must rely on the press release and upcoming 10-Q filing for revenue, margins, and traceability growth. The filing will reveal whether traceability revenue is accelerating.
XBP Global's Q1 2026 earnings call transcript ended before any financial data was disclosed. The actual SEC filing is the next catalyst for the stock.
The Q1 2026 earnings call transcript for Spanish REIT Colonial SFL (IMQCF) contains no financial figures. The official quarterly filing to the CNMV will provide the numbers investors need.
INNOVATE (VATE) Q1 2026 call previews filings for 60+ spectrum licenses; DBM Global adjusted backlog sits at $1.8B. Financials omitted until 10-Q filing.
Revenue fell 10% and EBITDA 35%, a beat against depressed expectations. Housing data and the Fed's next move will test whether the cyclical trough is priced in.
Cash rose to $7.5M after at-the-market equity sales, extending runway. Revenue miss of 20% signals pipeline challenges. Next catalyst: Q2 sales traction.
No revenue, test volume, or EPS figures appear in the initial transcript of Lucid Diagnostics' May 14 call. The market must wait for the 10-Q filing to assess EsoGuard adoption.
PBH's Q4 earnings transcript lacks revenue, EPS, and guidance. The only forward signal is a direct safe-harbor warning on supply chain constraints and high inflation.
GWRS Q1 2026 earnings call transcript contains no financial data, revenue, or regulatory update. Traders must use the separate May 13 press release for numbers.
The Q1 2026 slide deck appeared without detailed financials, leaving AAXBF traders waiting for the statutory filing to confirm whether the long-haul carrier maintained its momentum.
Canadian Tire Q1 diluted EPS C$2.02, revenue C$3.57B (+3.3%), normalized EPS C$2.00. The full filing will show if the revenue gain came from margin or discounting.
Mukul Kochhar sees Indian equities resilient on manufacturing exports, earnings recovery, and AI. HDFC Bank's Alpha Score 36 signals caution; Infosys at 57 shows moderate strength.
The May 13, 2026 transcript excluded Cisco's Q3 revenue and EPS figures. The company referenced Q4 and full-year FY26 guidance, though no numbers were disclosed.
Alibaba Cloud external revenue surged 40% as AI products hit 30% of sales. AI quarterly revenue was RMB 8.97B; ARR above RMB 35.8B signals recurring commitments.
Q1 GMS +7%, revenue +12%, EBITDA margin 16% on AI and deleveraging. Full-year guidance for $10.1B GMS, $420M EBITDA reaffirmed. Ticket demand the next catalyst.
Aytu BioPharma's Q3 call featured CEO Josh Disbrow and CFO Ryan Selhorn. Analysts probed cash burn and ADHD revenue. The 10-Q filing is the next catalyst.
Record $15.8B revenue and $1.06 EPS beat estimates; Cisco targets $9B in AI orders after $5.3B secured from hyperscalers. Shares jumped ~20% after-hours on restructuring plan.
The full Q1 2026 call transcript for Birchtech Corp. is now the primary document for assessing cash burn, revenue visibility, and the path to breakeven. The Q&A will set the stock's direction until the next filing.
Lulu's Fashion Lounge released its Q1 2026 earnings call transcript. The market now parses management commentary for revenue trends, margin pressure, and cash runway.
Cytosorbents' Q1 2026 earnings call on May 13 will reveal financials and pipeline updates that could swing CTSO shares. Key risk: cash runway and regulatory milestones.